Treatment-Naïve CLL: Fixed-Duration Therapy Is Non-Inferior to Continuous Treatment

At ASH Annual Meeting, DXY Expert Spotlights had the privilege of speaking with Dr. Othman Al-Sawaf from the University of Cologne, who presented the CLL17 phase III trial during the Plenary Scientific Session.